相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Mazyar Shadman et al.
LANCET HAEMATOLOGY (2023)
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004) a multicentre, open-label, single-arm, phase 1-2 study & nbsp;
Tanya Siddiqi et al.
LANCET (2023)
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
Barbara Eichhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Othman Al-Sawaf et al.
NATURE COMMUNICATIONS (2023)
S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
Arnon Kater et al.
HemaSphere (2023)
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E. Budde et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial
Tait D. Shanafelt et al.
BLOOD (2022)
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Paul M. Barr et al.
BLOOD ADVANCES (2022)
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia
Paul J. Hampel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C. Thompson et al.
BLOOD ADVANCES (2022)
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
Paolo Ghia et al.
HEMASPHERE (2022)
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Jennifer A. Woyach et al.
BLOOD (2022)
Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Jennifer A. Woyach et al.
BLOOD (2021)
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
HAEMATOLOGICA (2021)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings et al.
LANCET (2021)
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
Thomas E. Lew et al.
BLOOD ADVANCES (2021)
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare
Paul J. Hampel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
Victor S. Lin et al.
BLOOD (2020)
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Anthony R. Mato et al.
CLINICAL CANCER RESEARCH (2020)
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E. Roeker et al.
BLOOD ADVANCES (2020)
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia
Haesook T. Kim et al.
BLOOD ADVANCES (2020)
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Anne Quinquenel et al.
BLOOD (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL
Danielle M. Brander et al.
BLOOD (2019)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
CANCER DISCOVERY (2019)
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Anthony R. Mato et al.
BLOOD ADVANCES (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones et al.
LANCET ONCOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
分享论文
